Sagent Pharmaceuticals,
Inc. SGNT today announced the reintroduction of Amiodarone HCl
Injection, an antiarrhythmic agent, now in an improved prefilled plastic
syringe that is compatible with most standard I.V. pumps. According to IMS,
for the 12 months ending June 2013, the US market for Amiodarone HCl Injection
approximated $16 million. As with all products in Sagent's portfolio,
Amiodarone features Sagent's PreventIV Measures^SM packaging and labeling,
designed to help reduce medication errors.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in